Title: SENSITIZATION TO ANOTHER ANTI schwANCER THERAPY AND/OR AMELIORATION OF A SIDE EFFECT OF ANOTHER ANTI schwANCER THERAPY BY TREATMENT WITH A GST-ACTIVATED ANTI schwANCER COMPOUND

Abstract: The use of a GST-activated anticancer compound in the manufacture of a medicament for sensitizing a mammal, especially a human, to another anticancer therapy (that is, an anticancer therapy that is not treatment with a GST-activated anticancer compound - including chemotherapy, molecular targeted therapy, biologic therapy, and radiotherapy, each used as monotherapy or two or more used in combination), or for ameliorating a side effect of another anticancer therapy in a mammal, especially a human. Compositions containing a GST-activated anticancer compound for these uses. A method of sensitizing a mammal, especially a human, to another anticancer therapy, by administering a sensitizing effective amount of a GST activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST activated anticancer compound. The GST activated anticancer compound is preferably a compound of US Patent No. 5,556,942, and preferably canfosfamide, especially as the hydrochloride salt.
Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound

Technical Field

[0001] This invention relates to anticancer therapy.

Background Art

[0002] The purpose of anticancer therapy is to prevent cancer cells from multiplying, invading, metastasizing, and ultimately killing their host organism, e.g. a human or other mammal. Because cell multiplication is a characteristic of many normal cells as well as cancer cells, most anticancer therapies also have toxic effects on normal cells, particularly those with a rapid rate of turnover, such as bone marrow and mucous membrane cells. The goal in selecting an effective anticancer therapy, therefore, is to find a therapy that has a marked growth inhibitory or controlling effect on the cancer cells and a minimal toxic effect on the host. In the most effective therapies, the agents used are capable not only of inhibiting but also eradicating all cancer cells while sufficiently preserving normal cells to permit the host to return to normal or at least satisfactory life function and quality. Anticancer therapies include "classic" chemotherapy with antiproliferative agents (typically, small molecules) that target all dividing cells; molecular targeted therapy designed to specifically target cancer cells, such as functional therapy designed to alter a molecular function in the cancer cells with gene therapy, antisense therapy, and drugs such as erlotinib hydrochloride, gefitinib, and imatinib mesylate, and phenotype-directed therapy designed to target the unique phenotype of cancer cells such as therapy with monoclonal antibodies, immunotoxins, radioimmunoconjugates, and cancer vaccines; biologic therapy with cytokines such as interleukin-2 and interferon-α, and radiotherapy.

[0003] However, although the first effective anticancer compounds were brought into clinical trials in the 1940’s, initial therapeutic results were disappointing. Regressions of acute lymphocytic leukemia and adult lymphomas were obtained with single agents such as the nitrogen mustards, antifolates, corticosteroids, and vinca alkaloids, but responses were frequently partial and only of short duration; and relapse was associated with resistance to the original drug. Initial resistance to a given single agent (natural resistance) is frequent, and even initially responsive cancers frequently display acquired resistance after drug exposure, probably owing to selection of pre-existing resistant cancer cells from a heterogeneous population and
possibly also owing to an increased rate of mutation to resistance. This is consistent with the clinical observation that, with few exceptions, cancers are cured only by combination therapy. Cancers are frequently characterized as being resistant (not showing a response during the initial course of therapy) or refractory (having shown an initial response, then relapsed, and not showing a response on a later course of therapy) to anticancer therapies. Resistance to one anticancer drug, e.g. a platinum anticancer compound such as cisplatin, is often associated with cross-resistance to other drugs of the same class, e.g. other platinum compounds such as carboplatin. Multiple drug resistance, also called pleiotropic drug resistance, is a phenomenon where treatment with one drug confers resistance not only to that drug and others of its class but also to unrelated agents.

[0004] Anticancer therapies, especially chemotherapies, are frequently employed in combination, for several principal reasons. First, treatment with two or more non-cross-resistant therapies may prevent the formation of resistant clones; second, the combination of two or more therapies that are active against cells in different phases of growth (resting - G₀, postmitotic - G₁, DNA synthesis - S, premitotic - G₂, and mitotic – M) may kill cells that are dividing slowly as well as those that are dividing actively and/or recruit cells into a more actively dividing state, making them more sensitive to many anticancer therapies; and third, the combination may create a biochemical enhancement effect by affecting different pathways or different steps in a single biochemical pathway. Particularly when the toxicities of the therapies are non-overlapping, two or more therapies may be employed in full or nearly full amounts, and the effectiveness of each therapy will be maintained in the combination; thus, myelosuppressive drugs may be supplemented by non-myelosuppressive drugs such as the vinca alkaloids, prednisone, and bleomycin; and combination chemotherapies have been developed for a number of cancers that are not curable with single agents. Combinations of two or more of chemotherapy, molecular targeted therapy, biologic therapy, and radiotherapy are also known and used. Although the existence of a wide variety of mechanistically distinct anticancer therapies suggests that non-cross-resistant therapies can be found, cancer cells are known to possess a variety of mechanisms that confer pleiotropic drug resistance. These mechanisms of resistance contribute to the failure of combination therapy to cure common cancers such as metastatic colon cancer and prostate cancer.

[0005] A disadvantage of virtually all anticancer therapies is the occurrence of side effects, undesired effects caused by the anticancer therapy on a patient being treated for a cancer. While some effects are minor in their effect on the physical health of the patient, such as
alopecia (which is common in patients treated with platinum compounds, taxanes, and anthracyclines), most others such as nausea, vomiting, and neutropenia (also common in patients treated with platinum compounds) can have such an effect on the physical health of the patient that their occurrence limits the ability to treat the patient with the desired amount of the anticancer therapy and/or the willingness of the patient to undertake the anticancer therapy. Protective and adjunctive agents (as discussed in paragraph [0038] below) and antiemetics can be used to ameliorate some of the side effects of some anticancer therapies; however, in many instances, anticancer therapy is administered not at the amount that would be maximally effective against the cancer cells themselves, but in an amount at which the side effects of the therapy are tolerable or treatable, the maximum tolerated dose.

[0006] Discussions of anticancer chemotherapy and biologic therapy, and their side effects, and examples of suitable therapeutic protocols, may be found in such books as Cancer Chemotherapy and Biotherapy: Principles and Practice, 3rd ed. (2001), Chabner and Longo, eds., and Handbook of Cancer Chemotherapy, 6th ed. (2003), Skek, ed., both from Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, U.S.A.; and regimens for anticancer therapies, especially chemotherapies, may be found on Web sites such as those maintained by the National Cancer Institute (www.cancer.gov), the American Society for Clinical Oncology (www.asco.org), and the National Comprehensive Cancer Network (www.nccn.org).

[0007] Glutathione (GSH), in its reduced form, is a tripeptide of the formula:  
\[ \gamma-L-\text{Glu-L-Cys-Gly} \]. Reduced glutathione has a central role in maintaining the redox condition in cells and is also an essential substrate for glutathione S-transferase (GST). GST exists in mammals as a superfamily of isoenzymes which regulate the metabolism and detoxification of foreign substances introduced into cells. In general, GST can facilitate detoxification of foreign substances (including anticancer drugs), but it can also convert certain precursors into toxic substances. The isoenzyme GST P1-1 is constitutively expressed in many cancer cells, such as ovarian, non-small cell lung, breast, colorectal, pancreatic, and lymphoma tissue (more than 75% of human tumor specimens from breast, lung, liver, and colorectal cancers are reported to express GST P1-1). It is frequently overexpressed in tumors following treatment with many chemotherapeutic agents, and is seen in cancer cells that have developed resistance to these agents.

\[
\text{Y} - \text{H} - \text{N} - \text{C} - \text{O} - \text{S} - \text{R}^1 - \text{R}^2 - \text{R}^3 - \text{L}
\]

and their amides, esters, and salts, where:

- \(L\) is an electron withdrawing leaving group;
- \(S^x\) is \(-\text{S}(=\text{O})_2\), \(-\text{S}(=\text{O})\), \(-\text{S}(=\text{N})\), \(-\text{S}(=\text{O})(=\text{N})\), \(-\text{S}^4\text{(C}_1\text{-C}_6\text{ alkyl)}\), \(-\text{Se}(=\text{O})\), \(-\text{Se}(=\text{O})_2\), \(-\text{Se}(=\text{N})\), or \(-\text{Se}(=\text{O})(=\text{N})\); or is \(-\text{O} - \text{C}(=\text{O})\), or \(-\text{HN} - \text{C}(=\text{O})\);
- each \(\text{R}^1, \text{R}^2\) and \(\text{R}^3\) is independently \(\text{H}\) or a non-interfering substituent;
- \(n\) is 0, 1 or 2;

Y is selected from the group consisting of

\[
\begin{align*}
\text{H}_2\text{NCH(CH}_2\text{)}_m\text{CONHCH}_2\text{COOH} & \\
\text{HOOC(CH}_2\text{)}_m\text{CH} - \text{NH}_2 & \\
\text{H}_2\text{NCH(CH}_2\text{)}_m\text{CONHCH}_2\text{COOH} & \\
\text{HOOC(CH}_2\text{)}_m\text{CHCONHCH}_2\text{NH}_2
\end{align*}
\]

where \(m\) is 1 or 2; and

\(\text{AA}_c\) is an amino acid linked through a peptide bond to the remainder of the compound, and their syntheses.

[0009] The compounds of the patent are stated to be useful drugs for the selective treatment of target tissues which contain compatible GST isoenzymes, and simultaneously elevate the levels of GM progenitor cells in bone marrow. Disclosed embodiments for \(L\) include those that generate a drug that is cytotoxic to unwanted cells, including the phosphoramidate and phosphorodiamidate mustards.
[0010] One of the compounds identified in the patent has the formula

![Chemical Structure](image)

It is referred to in the patent as TER 286 and named as $\gamma$-glutamyl-$\alpha$-amino-$\beta$-[(2-ethyl-N,N,N,N-tetra(2'-chloro)ethylphosphoramidate)sulfonyl]propionyl-(R)-(R)-phenylglycine. This compound, later referred to as TLK286, has the CAS name L-$\gamma$-glutamyl-3-[[bis[bis(2-chloroethyl)amino]phosphinyloxy]ethyl]sulfonyl]-L-alanyl-2-phenyl-(2R)-glycine. As the neutral compound, its proposed International Nonproprietary Name is canfosfamide; and as its hydrochloride acid addition salt, its United States Adopted Name is canfosfamide hydrochloride. Canfosfamide and its salts are anticancer compounds that are activated by the actions of GST P1-1, and by GST A1-1, to release the cytotoxic phosphorodiamidate mustard moiety.

[0011] In vitro, canfosfamide has been shown to be more potent in the M6709 human colon carcinoma cell line selected for resistance to doxorubicin and the MCF-7 human breast carcinoma cell line selected for resistance to cyclophosphamide, both of which overexpress GST P1-1, over their parental cell lines; and in murine xenografts of M7609 engineered to have high, medium, and low levels of GST P1-1, the potency of canfosfamide hydrochloride was positively correlated with the level of GST P1-1 (Morgan et al., Cancer Res., 58:2568 (1998)).

[0012] Canfosfamide hydrochloride is currently being evaluated in multiple clinical trials for the treatment of ovarian, breast, non-small cell lung, and colorectal cancers. It has demonstrated significant single agent antitumor activity and improvement in survival in patients with non-small cell lung cancer and ovarian cancer, and single agent antitumor activity in colorectal and breast cancer. Evidence from in vitro cell culture and tumor biopsies indicates that canfosfamide is non-cross-resistant to platinum, paclitaxel, and doxorubicin (Rosario et al., Mol. Pharmacol., 58:167 (2000)), and also to gemcitabine. Patients treated with
canfosfamide hydrochloride show a very low incidence of clinically significant hematological toxicity.


[0014] Anticancer therapies are steadily evolving, but it remains true that even the best current therapies are not always even initially effective and frequently become ineffective after treatment, and are frequently accompanied by significant side effects, so that improved anticancer therapies are constantly being sought.

Disclosure of the Invention

[0015] In a first aspect, this invention is the use of a GST-activated anticancer compound in the manufacture of a medicament for sensitizing a mammal, especially a human, to another anticancer therapy, that is, an anticancer therapy that is not a treatment with a GST-activated anticancer compound (including chemotherapy, molecular targeted therapy, biologic therapy, or radiotherapy, each used as monotherapy or more than one used in combination).

[0016] In a second aspect, this invention is the use of a GST-activated anticancer compound in the manufacture of a medicament for ameliorating a side effect of another anticancer therapy in a mammal, especially a human.

[0017] In a third aspect, this invention is a pharmaceutical composition for sensitizing a mammal, especially a human, to another anticancer therapy, comprising a GST-activated anticancer compound and optionally an excipient.

[0018] In a fourth aspect, this invention is a pharmaceutical composition for ameliorating a side effect of another anticancer therapy in a mammal, especially a human, comprising a GST-activated anticancer compound and optionally an excipient.
[0019] In a fifth aspect, this invention is a method of sensitizing a mammal, especially a
human, to another anticancer therapy, comprising administering a sensitizing effective amount
of a GST-activated anticancer compound to the mammal.

[0020] In a sixth aspect, this invention is a method of ameliorating a side effect of another
anticancer therapy in a mammal, especially a human, comprising administering an ameliorating
effective amount of a GST-activated anticancer compound to the mammal.

[0021] In preferred embodiments of this invention (preferred embodiments of the uses,
compositions, and methods of this invention as mentioned in paragraphs [0015]
through [0020] above), the GST-activated anticancer compound is a compound that is an
inhibitor, especially an irreversible inhibitor, of one or more GST isoenzymes and/or is a
compound of US Patent No. 5,556,942, especially canfosfamide or an amide, ester,
amide/ester, or salt thereof, particularly canfosfamide or a salt thereof, especially canfosfamide
hydrochloride; and these preferences and preferred another anticancer therapies for which the
sensitization and/or amelioration by the GST-activated anticancer compound may be used are
characterized by the specification and by the features of use claims 2 through 23 of this
application as filed.

[0022] In a particular embodiment of the invention, the sensitization therapy of this invention
excludes sensitization to oxaliplatin by canfosfamide and its salts, especially canfosfamide
hydrochloride, and/or excludes sensitization to paclitaxel or sensitization to taxanes by
canfosfamide and its salts, especially canfosfamide hydrochloride, and/or excludes
sensitization by canfosfamide and its salts, especially canfosfamide hydrochloride, at a dose of
500 mg/m² or more.

[0023] In another particular embodiment of this invention, the amelioration therapy excludes
amelioration of a side effect of another anticancer therapy by canfosfamide and its salts,
especially canfosfamide hydrochloride, at a dose of 500 mg/m² or more.

Modes for Carrying Out the Invention

[0024] The GST-activated anticancer compound

[0025] A “GST-activated anticancer compound” is a compound comprising glutathione or a
glutathione analog chemically linked to a cytotoxic moiety such that the cytotoxic moiety is
released by cleavage from the glutathione or glutathione analog in the presence of one or more
GST isoenzymes.
[0026] Suitable such compounds include those disclosed in US Patent No. 5,556,942 and are of the formula

![Chemical Structure](image)

and their amides, esters, amide-esters, and salts of all these compounds, where:

5  
L is a cytotoxic electron withdrawing leaving group;

$S^x$ is $-S(=O)_{2}$, $-S(=O)$, $-S(=O)(=NH)$, $-S(=O)(=NH)_2$, $-S^+(C_1-C_4$ alkyl$)$, $-Se(=O)_{2}$, $-Se(=O)$, or $-Se(=O)(=NH)$, or is $-O-C(=O)$, or $-HN-C(=O)$;

each of $R^1$, $R^2$ and $R^3$ is independently H or a non-interfering substituent, such as H,

10  
optionally substituted $C_1-C_6$ alkyl (for example, methyl, tert-butyl, cyclohexyl, and the like),

optionally substituted $C_6-C_{12}$ aryl (for example, phenyl, naphthyl, pyridyl, and the like),

optionally substituted $C_7-C_{12}$ aralkyl (for example, benzyl, phenylethyl, 2-pyridylethyl, and the like), cyano, halo, optionally substituted $C_1-C_6$ alkoxy, optionally substituted $C_6-C_{12}$ arylalkoxy, or

optionally substituted $C_7-C_{12}$ aralkoxy, where the optional substituents may be halo, -OR, -SR, or -NR$_2$, where R is H or $C_1-C_4$ alkyl;

15  
n is 0, 1 or 2;

Y is selected from the group consisting of

$\text{H}_2\text{NCH(CH}_2\text{H}_m\text{CH}--\text{COOH}$, $\text{HOOC(CH}_2\text{H}_m\text{CH}--\text{NH}_2$, $\text{H}_2\text{NCH(CH}_2\text{H}_m\text{CONHCH}_2--\text{COOH}$, and

$\text{HOOC(CH}_2\text{H}_m\text{CHCONHCH}_2--\text{NH}_2$

where $m$ is 1 or 2; and

AA$_c$ is an amino acid linked through a peptide bond to the remainder of the compound.

20  
[0027] In preferred embodiments, one or more of the following preferences is met:

L is a toxin such as ricin or diphtheria toxin, a linkable anticancer agent such as doxorubicin or
daunorubicin, or a phosphoramidate or phosphorodiamidate mustard, especially a
phosphorodiamidate mustard of the formula $-\text{OP}(=O)(\text{NHCH}_2\text{CH}_2X)_2$ or

$-\text{OP}(=O)(\text{N(CH}_2\text{CH}_2X)_2)_2$, particularly of the formula $-\text{OP}(=O)(\text{N(CH}_2\text{CH}_2X)_2)_2$, where X is

25  
Cl or Br, especially Cl;

$S^x$ is $-S(=O)_{2}$;
R\textsuperscript{1} is H, C\textsubscript{1}-C\textsubscript{4} alkyl, or phenyl, especially H or phenyl, particularly H;
each R\textsuperscript{2} is independently chosen from H and C\textsubscript{1}-C\textsubscript{6} alkyl, especially H;
each R\textsuperscript{3} is independently chosen from H, C\textsubscript{1}-C\textsubscript{4} alkyl, and phenyl, especially H;
n is 0;

5 Y-C(=O)- is γ-glutamyl, especially L-γ-glutamyl;
AA\textsubscript{4} is glycine, phenylglycine, β-alanine, alanine, phenylalanine, valine, 4-aminobutyric acid,
aspartic acid, histidine, tryptophan, and tyrosine, as either the (S)- or (R)-isomers, optionally
substituted on the phenyl ring as described above for R\textsuperscript{1} through R\textsuperscript{3}, especially glycine,
phenylglycine, β-alanine, alanine, or phenylalanine, and particularly (R)-phenylglycine.

10 [0028] Suitable amides and esters of these compounds include those in which one or both of
the carboxyl groups is amidated or esterified to form a C\textsubscript{1}-C\textsubscript{4} alkyl or alkenyl, C\textsubscript{6}-C\textsubscript{10} aryl, or
C\textsubscript{7}-C\textsubscript{14} aralkyl amide or ester, in which the alkyl or aryl groups may be optionally substituted
with noninterfering substituents such as halo, alkoxy, or alkylamino. The amides and esters
may be monoamides or diamides, monoesters or diesters, or monoamide-monoesters.

15 Suitable salts (see Berge et al., J. Pharm. Sci., 66:1 (1971) for a nonexclusive list) are those
formed when inorganic bases (e.g. sodium, potassium, and calcium hydroxide) or organic
bases (e.g. ethanolamine, diethanolamine, triethanolamine, ethylenediamine, tromethamine,
N-methylglucamine) react with the carboxyl groups, and those formed when inorganic acids
(e.g. hydrochloric, hydrobromic, sulfuric, nitric, and chlorosulfonic acids) or organic acids
(e.g. acetic, propionic, oxalic, malic, maleic, malonic, fumaric, or tartaric acids, and alkane-
or arenesulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic, substituted
benzenesulfonic such as chlorobenzenesulfonic and toluenesulfonic, naphthalenesulfonic and
substituted naphthalenesulfonic, naphthalenedisulfonic and substituted naphthalenedisulfonic,
and camphorsulfonic acids) react to form acid addition salts of the amine groups. Mixed
amide salts and ester salts are also included, as are hydrates and other solvates as well as
unsolvated forms.

[0029] The preparation of these compounds and their derivatives may be made by methods
well known to the person of ordinary skill in the art and as described in US Patent No.
5,556,942.

20 [0030] A particularly preferred GST-activated anticancer compound is canfosfamide (i.e.
L-γ-glutamyl-3-[[2-[[bis[bis(2-chloroethyl)amino]phosphinyl]oxy]ethyl]sulfonyl]-L-alanyl-
2-phenyl-(2R)-glycine) or its salts, especially canfosfamide hydrochloride.
[0031] As a monotherapy for a number of cancers, including ovarian, breast, non-small cell lung, and colorectal cancers, canfosfamide hydrochloride has been administered by intravenous infusion at doses of 400 - 1000 mg/m² body surface area at once/week and once/three weeks.

[0032] As a combination therapy with cisplatin (75 and 100 mg/m²), canfosfamide hydrochloride has been administered at 750 and 1000 mg/m² at 3-weekly intervals. As a combination therapy with carboplatin (AUC 5 or 6 mg/mL•min), canfosfamide hydrochloride has been administered at 500, 750, and 960 mg/m² at 3- to 4-weekly intervals. As a combination therapy with docetaxel (75 mg/m²), canfosfamide hydrochloride has been administered at 500, 750, and 960 mg/m² at 3-weekly intervals. As a combination therapy with liposomal doxorubicin (40 or 50 mg/m²), canfosfamide hydrochloride has been administered at 500, 750, and 960 mg/m² at 4-weekly intervals. As a combination therapy with paclitaxel (200 mg/m²) and carboplatin (AUC 6 mg/mL•min), canfosfamide hydrochloride has been administered at 400, 500, 750, and 1000 mg/m² at 3-weekly intervals.

[0033] Another anticancer therapy

[0034] “Another anticancer therapy” is an anticancer therapy that is not a treatment with a GST-activated anticancer compound, especially an anticancer therapy that is not a treatment with a compound disclosed in paragraphs [0025] to [0030] above. Such “another anticancer therapies” include chemotherapy, molecular targeted therapy, biologic therapy, and radiotherapy. These therapies are those used as monotherapy or in combination therapy.

[0035] Chemotherapeutic agents include:
alkylating agents, including:
alkyl sulfonates such as busulfan,
ethyleneimine derivatives such as thiopeta,
nitrogen mustards such as chlorambucil, cyclophosphamide, estramustine, ifosfamide,
mechlorethamine, melphalan, and uramustine,
nitrosoureas such as carmustine, lomustine, and streptozocin,
triazenes such as dacarbazine, procarbazine, and temozolamide, and
platinum compounds such as cisplatin, carboplatin, oxaliplatin, satraplatin, and picoplatin;
antimetabolites, including:
antifolates such as methotrexate, permutrexed, raltitrexed, and trimetrexate,
purine analogs such as cladribine, chlorodeoxyadenosine, clofarabine, fludarabine,
mercaptopurine, pentostatin, and thioguanine,
pyrimidine analogs such as azacitidine, capecitabine, cytarabine, edatrexate, floxuridine,
fluorouracil, gemcitabine, and troxacitabine;
natural products, including:
antitumor antibiotics such as bleomycin, dactinomycin, mithramycin, mitomycin,
mitoxantrone, porfiromycin, and anthracyclines such as daunorubicin (including liposomal
daunorubicin), doxorubicin (including liposomal doxorubicin), epirubicin, idarubicin, and
valrubicin,
enzymes such as L-asparaginase and PEG-L-asparaginase,
microtubule polymer stabilizers such as the taxanes paclitaxel and docetaxel,
mitotic inhibitors such as the vinca alkaloids vinblastine, vincristine, vindesine, and
vinorelbine,
topoisomerase I inhibitors such as the camptothecins irinotecan and topotecan, and
topoisoasemase II inhibitors such as amsacrine, etoposide, and teniposide;
hormones and hormone antagonists, including:
androgens such as fluoxymesterone and testolactone,
antiandrogens such as bicalutamide, cyproterone, flutamide, and nilutamide,
aromatase inhibitors such as aminoglutethimide, anastrozole, exemestane, formestane, and
letrozole,
corticosteroids such as dexamethasone and prednisone,
estrogens such as diethylstilbestrol,
antiestrogens such as fulvestrant, raloxifene, tamoxifen, and toremifene,
LHRH agonists and antagonists such as buserelin, goserelin, leuprolide, and triptorelin,
progestins such as medroxyprogesterone acetate and megestrol acetate, and
thyroid hormones such as levothyroxine and liothyronine; and
miscellaneous agents, including altretamine, arsenic trioxide, gallium nitrate, hydroxyurea,
levamisole, mitotane, octreotide, procarbazine, suramin, thalidomide, lenalidomide,
photodynamic compounds such as methoxsalen and sodium porfimer, and proteasome
inhibitors such as bortezomib.

[0036] Molecular targeted therapy agents include:
functional therapeutic agents, including:
gene therapy agents,
antisense therapy agents,
tyrosine kinase inhibitors such as erlotinib hydrochloride, gefitinib, imatinib mesylate, and semaxanib, and
gene expression modulators such as the retinoids and rexinoids, e.g. adapalene, bexarotene, 
*trans*-retinoic acid, *9-cis*-retinoic acid, and N-(4-hydroxyphenyl)retinamide;
phenotype-directed therapy agents, including:
monoclonal antibodies such as alemtuzumab, bevacizumab, cetuximab, ibritumomab tiuxetan,
rituximab, and trastuzumab,
immunotoxins such as gemtuzumab ozogamicin,
radioimmunoconjugates such as *131*I-tositumomab, and
10 cancer vaccines.

[0037] Biologic therapy agents include:
interferons such as interferon-α2a and interferon-α2b, and
interleukins such as aldesleukin, denileukin diftitox, and oprelvekin.

[0038] In addition to these agents intended to act against cancer cells, anticancer therapies
include the use of protective or adjunctive agents, including:
cytoprotective agents such as amifostine, dexrazoxane, and mesna,
phosphonates such as pamidronate and zoledronic acid, and
stimulating factors such as epoetin, darbeopetin, filgrastim, PEG-filgrastim, and sargramostim.

[0039] Combination anticancer therapy regimens to which the GST-activated anticancer
compound may be used to sensitize a mammal to and/or for which the GST-activated anticancer
compound can be used to ameliorate a side effect of that therapy include all
regimens involving the use of two or more of the anticancer therapies (anticancer agents) such
as those mentioned in paragraphs [0034] to [0037] above (for example, a platinum compound
and a taxane) and/or radiotherapy, optionally including protective and adjunctive agents such
as those mentioned in paragraph [0038] above; and the GST-activated anticancer compound
can be used to sensitize a mammal to and/or ameliorate a side effect of existing anticancer
regimens known for the treatment of various cancers, such as the regimens mentioned in the
documents cited in paragraph [0006] above.

[0040] Many combination chemotherapeutic regimens are known to the art, such as
combinations of platinum compounds and taxanes, e.g. carboplatin/paclitaxel,
capecitabine/docetaxel, the "Cooper regimen", fluorouracil-levamisole, fluorouracil-
leucovorin, methotrexate-leucovorin, and those known by the acronyms ABDIC, ABVD, AC,
ADIC, AI, BACOD, BACOP, BVCP, CABO, CAD, CAE,CAF, CAP, CD, CEC, CF, CHOP, CHOP+rituximab, CIC, CMF, CMFP, CyADIC, CyVADIC, DAC, DVD, FAC, FAC-S, FAM-S, FOLFOX-4, FOLFOX-6, M-BACOD, MACOB-B, MAID, MOPP, MVAC, PCV, T-5, VAC, VAD, VAPA, VAP-Cyclo, VAP-II, VBM, VBMCP, VIP, VP, and the like.

5 [0041] Combinations of chemotherapies and molecular targeted therapies, biologic therapies, and radiation therapies are also well known to the art; including therapies such as trastuzumab + paclitaxel, alone or in further combination with carboplatin, for certain breast cancers, and many other such regimens for other cancers; and the "Dublin regimen" (555 mg/m² fluorouracil IV over 16 hours on days 1 – 5 and 75 mg/m² cisplatin IV over 8 hours on day 7, with repetition at 6 weeks, in combination with 40 Gy radiotherapy in 15 fractions over the first 3 weeks) and the "Michigan regimen" (fluorouracil + cisplatin + vinblastine + radiotherapy), both for esophageal cancer, and many other such regimens for other cancers.

Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound

15 [0042] This invention is a method of sensitizing a mammal, especially a human, to another anticancer therapy, comprising administering a sensitizing effective amount of a GST-activated anticancer compound to the mammal; and is also a method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, comprising administering an ameliorating effective amount of a GST-activated anticancer compound to the mammal.

[0043] A “sensitizing effective amount” of the GST-activated anticancer compound means that amount which, when administered to a mammal, especially a human, for treating a cancer with another anticancer therapy, is sufficient to sensitize the mammal to the another anticancer therapy. “Sensitizing” or “sensitization” of a mammal to another anticancer therapy includes one or both of:

(1) increasing the efficacy of the another anticancer therapy in a mammal naïve to that therapy (“initial sensitization”), and

(2) increasing the efficacy of the another anticancer therapy in a mammal that has already received that therapy, in particular in a mammal that has received that therapy and been refractory or become resistant to it (“resensitization”).

[0044] In the case of initial sensitization, increasing the efficacy of the another anticancer therapy includes causing the therapeutically effective amount of that another anticancer
therapy to be lower than it would be if the initial sensitization had not occurred (so that a lesser dose and/or reduced frequency of dosing can be used to achieve the same anticancer effect, thereby achieving equally effective therapy with that another anticancer therapy with no or fewer side effects), causing the amount of the another anticancer therapy that is therapeutically effective if the initial sensitization had not occurred to be more effective (so that a greater anticancer effect is achieved at the same amount of the another anticancer therapy), and/or inhibiting the development of resistance to the another anticancer therapy (preventing, delaying the onset of, and/or limiting the extent of resistance to that therapy). In the case of resensitization, increasing the efficacy of the another anticancer therapy includes these same effects described for initial sensitization, and particularly includes enabling the therapeutically effective reuse of another anticancer therapy to which resistance has developed (enabling the re-treating of a cancer with another anticancer therapy that, prior to the resensitization, had become resistant or refractory to that therapy).

[0045] An “ameliorating effective amount” of the GST-activated anticancer compound means that amount which, when administered to a mammal, especially a human, being treated for a cancer with another anticancer therapy, is sufficient to ameliorate one or more of the side effects of the another anticancer therapy. “Ameliorating” or “amelioration” of a side effect of another anticancer therapy includes one or more of:

1. preventing the occurrence of that side effect; and
2. limiting the severity of that side effect.

[0046] The side effects that may be ameliorated by treatment with the GST-activated anticancer compound may include any one or more of the known side effects of the another anticancer therapy. Such side effects include alopecia, nausea and/or vomiting, hematologic side effects such as neutropenia, neurologic side effects such as peripheral neuropathy, and the like.

[0047] A “therapeutically effective amount” of the another anticancer therapy means that amount which, when administered to a mammal, especially a human, for treating a cancer, is sufficient to effect treatment for the cancer. “Treating” or “treatment” of a cancer in a mammal includes one or more of:

1. inhibiting growth of the cancer, i.e., arresting its development,
2. preventing spread of the cancer, i.e. preventing metastases,
3. relieving the cancer, i.e., causing regression of the cancer,
preventing recurrence of the cancer, and
palliating symptoms of the cancer.

[0048] Cancers which may be effectively treated by the method of this invention include mammalian cancers, especially human cancers. Cancers that are particularly treatable by the method of this invention are cancers with sensitivity to inducers of apoptosis, and more specifically those cancers that express or, particularly, overexpress one or more glutathione S-transferase isoenzymes. Cancers that express or overexpress one or more glutathione S-transferase isoenzymes when treated with other anticancer compounds or combination anticancer chemotherapy regimens (i.e. those not including a GST-activated anticancer compound) are especially treatable by the method of this invention. Such cancers include cancers of the brain, breast, bladder, cervix, colon and rectum, esophagus, head and neck, kidney, lung, liver, ovary, pancreas, prostate, and stomach; leukemias such as ALL, AML, AMML, CLL, CML, CMML, and hairy cell leukemia; Hodgkin’s and non-Hodgkin’s lymphomas; mesotheliomas, multiple myeloma; and sarcomas of bone and soft tissue. Cancers particularly treatable by the method of this invention with canfosfamide and its salts as the GST-activated anticancer compound include breast, ovarian, colorectal, and non-small cell lung cancers; and TLK296 would also be useful for the same cancers because it also is activated by GST P1-1. Other GST-activated anticancer compounds are expected to be suitable for these or other cancers depending on the nature of the GST isoenzymes expressed by the cancer being treated.

[0049] Another anticancer therapies which may particularly benefit from the sensitization and/or amelioration method of this invention are those therapies where one or more GST isoenzymes are implicated in the action of that anticancer therapy; and particularly therapies involving the administration of platinum compounds such as cisplatin, carboplatin, oxaliplatin, satraplatin, and picoplatin, especially cisplatin and carboplatin; taxanes, such as paclitaxel and docetaxel; and anthracyclines such as daunorubicin, doxorubicin, epirubicin, idarubicin, and valrubicin. Thus the method of this invention particularly includes the sensitization to anticancer therapies involving platinum compounds, taxanes, and anthracyclines by administering a GST-activated anticancer compound of this invention; and the amelioration of a side effect, such as alopecia, of anticancer therapies involving platinum compounds, taxanes, and anthracyclines by a GST-activated anticancer compound of this invention.
[0050] The method of this invention therefore also comprises the administration of a sensitizing and/or ameliorating effective amount of a GST-activated anticancer compound and a therapeutically active amount of another anticancer therapy. The another anticancer therapy will generally be one that has utility in the treatment of the cancer being treated even without the sensitization and/or amelioration effect of the GST-activated anticancer compound; and a suitable such another anticancer therapy for a particular cancer to be treated will be determinable by a person of ordinary skill in the art having regard to that knowledge and this disclosure. It is of course contemplated that the sensitization and/or amelioration therapy of this invention may be used with anticancer therapies not yet in use. The GST-activated anticancer agent may also be used as adjuvant or neoadjuvant therapy accompanying radiation therapy.

[0051] For sensitization, the amount of the GST-activated anticancer compound that is administered to the mammal should be a sensitizing effective amount for the another anticancer therapy; and similarly the amount of the another anticancer therapy that is administered to the mammal should be a therapeutically effective amount when the mammal has been sensitized with the GST-activated anticancer compound. However, the sensitizing effective amount of the GST-activated anticancer compound may be different depending on the another anticancer therapy; and the therapeutically effective amount of the another anticancer therapy when administered in the method of this invention may be less than the amount which would be therapeutically effective if delivered to the mammal without sensitization. It is common in cancer therapy, though, to use the maximum tolerated dose of the or each therapy, with a reduction only because of common toxicity of the therapies used or potentiation of the toxicity of one therapy by another. Because of the lack of cross-resistance of canfosfamide and its salts, especially canfosfamide hydrochloride, for example, with several common chemotherapeutic agents, and its relative lack of clinically severe toxicity, especially its lack of clinically severe hematological toxicity, it is expected that no reduction in the amount of the another anticancer therapy will be required.

[0052] For amelioration, the amount of the GST-activated anticancer compound that is administered to the mammal should be an ameliorating effective amount for the another anticancer therapy; and similarly the amount of the another anticancer therapy that is administered to the mammal should be a therapeutically effective amount when a side effect has been ameliorated with the GST-activated anticancer compound. However, the ameliorating effective amount of the GST-activated anticancer compound may be different
depending on the another anticancer therapy; and the therapeutically effective amount of the another anticancer therapy when administered in the method of this invention may be less than the amount which would be therapeutically effective if delivered to the mammal without amelioration (since the GST-activated anticancer compound may also sensitize the mammal to that another anticancer therapy, as discussed elsewhere in this application). It is common in cancer therapy, though, to use the maximum tolerated dose of the or each therapy, with a reduction only because of common toxicity of the therapies used or potentiation of the toxicity of one therapy by another. Because of the lack of cross-resistance of canfosfamide and its salts, especially canfosfamide hydrochloride, for example, with several common chemotherapeutic agents, and its relative lack of clinically severe toxicity, especially its lack of clinically severe hematological toxicity, it is expected that no reduction in the amount of the another anticancer therapy will be required; and the amount of the another anticancer therapy that may be able to be administered may be higher than the usual dosage because of the amelioration of a side effect of that another anticancer therapy provided by the GST-activated anticancer compound.

[0053] The sensitization and/or amelioration therapy may involve the administration of the GST-activated anticancer compound before or during the administration of the another anticancer therapy. The administration of the GST-activated anticancer compound may precede at least one aspect of the another anticancer therapy (such as the administration of one dose of a chemotherapeutic agent, molecular targeted therapy agent, biologic therapy agent, or radiation therapy) by as little as a few minutes (for example, during the same day, e.g. during the same treatment visit) to as much as several weeks, for example from one to five weeks, e.g. one to three weeks.

[0054] Although not wishing to be bound by theory, it is considered that sensitization and/or amelioration therapy with the GST-activated anticancer compound, particularly a GST P1-1 activated anticancer compound such as canfosfamide and its salts, especially canfosfamide hydrochloride, and another anticancer therapy will be of benefit because of one or both of the following mechanisms:

(1) GST P1-1 is overexpressed in many cancer cell lines, and particularly in cell lines treated with known anticancer therapies such as treatment with platinum-containing compounds and doxorubicin; and the increase in GST P1-1 is correlated with an increase in resistance to the anticancer therapy. Because compounds such as canfosfamide are activated by GST P1-1, cancer cells that have been treated with another anticancer therapy will contain an elevated
level of GST P1-1 and will therefore increase the activity of canfosfamide in these cells. Thus a GST-activated anticancer compound such as canfosfamide or its salt will be especially potent in resensitization and in sensitization in cancer cells that already overexpress GST P1-1. Likewise other GST-activated anticancer compounds activated by other GST isoenzymes may be especially effective as sensitizers in cancers in which those other GST isoenzymes are implicated; and

(2) Compounds such as canfosfamide are activated by GST P1-1, and this activation is achieved by interaction of the canfosfamide with the active site of the enzyme. This interaction will limit the ability of the enzyme to interact with and detoxify other anticancer agents which might otherwise be detoxified by GST P1-1, thereby effectively increasing the cytotoxicity of (reducing the therapeutically effective amount of) these other anticancer agents. Thus administration of a GST-activated anticancer compound such as canfosfamide or its salt as a sensitizing agent will make the another anticancer therapy more effective than it would have been without the sensitization, and may re-enable use of another anticancer therapy to which the cancer has become resistant or refractory. In particular, because certain of these GST-activated anticancer compounds, such as canfosfamide, are irreversible inhibitors of GST P1-1, they may be especially effective in the sensitization method of this invention. Likewise, other GST-activated anticancer compounds interacting with and/or inhibiting other GST isoenzymes may be especially effective as sensitizers in cancers in which those other GST isoenzymes are implicated. Insofar as the toxicities (side effects) of any of the another anticancer therapies may be influenced by the interaction of the another anticancer therapies with a GST isoenzyme (such as GST P1-1), inhibition of the GST isoenzymes may also ameliorate a side effect of that another anticancer therapy, and thus GST-activated anticancer compounds like canfosfamide and its salts may be especially effective as ameliorators of the side effects of these anticancer therapies.

[0055] Suitable sensitization and/or amelioration dosing for canfosfamide or its salt as the GST-activated anticancer compound may be the same as the usual therapeutic dose, but will preferably be below the usual therapeutic dose, such as about 5 – 75% of the usual therapeutic dose, e.g. about 10 – 50% of the usual therapeutic dose, such as 20%, 25%, or 30% of the usual therapeutic dose; for example about 60 - 450 mg/m² body surface area, especially 125 - 450 mg/m² for canfosfamide hydrochloride. Dosing may be at 1 - 35 day intervals; for example, about 125 - 450 mg/m² at 1 - 5 week intervals, especially at 1, 2, 3, or 4 week intervals, or at higher frequencies including as frequently as once/day for several (e.g. 5 or 7)
days, with the dosing repeated every 2, 3, or 4 weeks, or constant infusion for a period of 6 - 72 hours, also with the dosing repeated every 2, 3, or 4 weeks; and such dosing flexibility will readily enable sensitization and/or amelioration for the anticancer therapies now used. Suitable dosages and dose frequencies for other GST-activated anticancer compounds will also preferably be below the usual therapeutic dose, such as about 5 - 50% of the usual therapeutic dose, e.g. 10 - 50% of the usual therapeutic dose, and will be readily determinable by a person of ordinary skill in the art having regard to that skill and this disclosure.

[0056] Suitable dosing for the other anticancer therapy will be the dosing already established for that therapy, as described in documents such as those cited in paragraph [006], recognizing that the therapeutically effective amount of the another anticancer therapy may be reduced by the sensitization of this invention. Such dosing varies widely with the therapy: for example, capecitabine (2500 mg/m² orally) is dosed twice daily for 2 weeks on and 1 week off, imatinib mesylate (400 or 600 mg/day orally) is dosed daily, rituximab is dosed weekly, paclitaxel (135 - 175 mg/m²) and docetaxel (60 - 100 mg/m²) are dosed weekly to every three weeks, carboplatin (AUC 4 - 6 mg/mL•min) is dosed once every 3 or 4 weeks (though the doses may be split and administered over several days), nitrosourea alkylating agents such as carmustine are dosed as infrequently as once every 6 weeks. Radiotherapy may be administered as frequently as weekly (or even within that split into smaller dosages administered daily).

[0057] A person of ordinary skill in the art of anticancer therapy will be able to ascertain a sensitizing and/or ameliorating effective amount of the GST-activated anticancer compound and a therapeutically effective amount of another anticancer therapy for a given cancer and stage of disease without undue experimentation and in reliance upon personal knowledge and the disclosure of this application.

[0058] The GST-activated anticancer compound and the another anticancer therapy may be administered by any route suitable to the subject being treated and the nature of the subject's condition. Routes of administration include, but are not limited to, administration by injection, including intravenous, intraperitoneal, intramuscular, and subcutaneous injection, by transmucosal or transdermal delivery, through topical applications, nasal spray, suppository and the like or may be administered orally. Formulations may optionally be liposomal formulations, emulsions, formulations designed to administer the drug across mucosal membranes or transdermal formulations. Suitable formulations for each of these methods of
administration may be found, for example, in *Remington: The Science and Practice of Pharmacy*, 20th ed., A. Gennaro, ed., Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, U.S.A.

Typical formulations will be either oral (as for compounds such as capecitabine) or solutions for intravenous infusion. Typical dosage forms will be tablets (for oral administration), solutions for intravenous infusion, and lyophilized powders for reconstitution as solutions for intravenous infusion. Although anticancer therapies are usually administered systemically, it is contemplated that the GST-activated anticancer compound may also be administered regionally, such as peritumorally or intratumorally, to sensitize the cancer to the another anticancer therapy administered either systemically or regionally.

[0059] Another anticancer therapies considered of particular present interest for sensitization or side effect amelioration by the method of this invention, especially with canfosfamide or its salt, include: a platinum compound such as carboplatin or cisplatin, optionally in combination with gemcitabine or a taxane such as docetaxel or paclitaxel; with gemcitabine; a taxane; an anthracycline such as doxorubicin or liposomal doxorubicin; oxaliplatin, optionally in combination with capecitabine or fluorouracil/leucovorin; and gemcitabine or a platinum compound such as carboplatin or cisplatin, in combination with a vinca alkaloid such as vinorelbine. It will be seen from the *in vitro* example that follows that canfosfamide hydrochloride causes sensitization to paclitaxel and, as mentioned previously, it is expected that canfosfamide or its salts or other GST-activated anticancer compounds can be used to sensitize to other anticancer therapies generally; and it will be seen from the clinical observation that follows that canfosfamide hydrochloride ameliorates the alopecia side effect of carboplatin and, as mentioned previously, it is expected that canfosfamide and its salts or other GST-activated anticancer compounds can be used to ameliorate one or more side effects of other anticancer therapies generally.

[0060] *In vitro* example

[0061] The following example illustrates the beneficial effect of canfosfamide, a GST-activated anticancer compound, in sensitizing human cancer cell lines *in vitro* to the effect of another anticancer agent. This result is considered predictive of efficacy in human anticancer chemotherapy, as each of canfosfamide and the other anticancer agent tested have shown anticancer activity in humans.

[0062] Cancer cell line. The human cancer cell line OVCAR-3 (ovarian adenocarcinoma) was obtained from the National Cancer Institute, Bethesda, Maryland, U.S.A.
Anticancer compounds. Canfosfamide was prepared for Telik. Paclitaxel was obtained from Sigma-Aldrich Chemical Company, St. Louis, Missouri, U.S.A.

**Example 1: Canfosfamide hydrochloride and paclitaxel**

A paclitaxel-resistant derivative cell line OVCAR-PR was developed from the human ovarian cancer cell line OVCAR-3 by growing OVCAR-3 cells in gradually increasing concentrations (up to 5 nM) of paclitaxel. A canfosfamide-modified derivative cell line OVCAR-TLK was developed by growing OVCAR-3 cells in gradually increasing concentrations (up to 6.5 μM) of canfosfamide. To maintain the phenotypes of the cell lines, the cells were treated with the compounds at weekly intervals. Cells were grown in compound-free media for 24 hours before any experiments.

**Cytotoxicity assay.** Log-phase cells were seeded in 96-well plates and incubated with the diluted compound or solvent for 2-3 doubling times. The extent of cell growth was quantitated using the CellTiter-Glo assay (Promega Corporation, Madison, Wisconsin, U.S.A.), used in accordance with the assay kit directions. The amount of ATP in the lysate, which corresponds to the number of viable cells, was quantitated using a luminometer. All assays were conducted in triplicate wells, with solvent control. The extent of cell growth was expressed as a percentage of the signal from the solvent control wells. The mean of the triplicate wells was computed and IC\textsubscript{50} determined using PrismGraph.

**Cell doubling time.** 1.5 × 10\textsuperscript{4} cells were seeded in a 25-mL flask. The cells were grown for four days and the number of viable cells was determined by Trypan Blue staining and manual counting using a hemocytometer. The assay was conducted in triplicate at each time point. The times for two cell doublings for OVCAR-3 and OVCAR-TLK cells were approximately 3.5 and 5.5 days, respectively.

Results: The IC\textsubscript{50} for paclitaxel increased from 1.3 nM in OVCAR-3 cells to 49 nM in OVCAR-PR cells, a more than 35-fold increase in resistance. However, the IC\textsubscript{50} for canfosfamide increased from 1.3 μM in OVCAR-3 cells to only 1.6 μM nM in OVCAR-PR cells, only a 1.2-fold increase in resistance. When the OVCAR-PR cells were first treated overnight with 4 μM canfosfamide, then tested for their response to paclitaxel, the IC\textsubscript{50} for paclitaxel decreased approximately 3-fold, indicating sensitization of these formerly paclitaxel-resistant cells by treatment with canfosfamide. When OVCAR-3 and OVCAR-TLK cells were treated with paclitaxel for equal treatment times, the IC\textsubscript{50}s for paclitaxel were approximately the same, but when the cells were treated for treatment times adjusted for the differential
doubling times (treated for approximately two doubling times), the IC₅₀ for paclitaxel of was about 2-fold lower in the OVCAR-TLK cells, indicating sensitization of even these non-paclitaxel-resistant cells by treatment with canfosfamide. OVCAR-3 and OVCAR-TLK cells were approximately equally sensitive to canfosfamide when treated for approximately two doubling times.

[0069] Therapeutic example

[0070] Sensitization to another anticancer therapies with canfosfamide

[0071] Canfosfamide hydrochloride at an initial dose of 500 mg/m² is administered intravenously, followed 30 minutes later by the intravenous administration of oxaliplatin at a therapeutically effective dose such as 85 mg/m². The canfosfamide hydrochloride dose may be increased to 850 mg/m² and further to 1280 mg/m², and the oxaliplatin dose may also be varied. This combination is administered at 2-weekly intervals.

[0072] Canfosfamide hydrochloride at an initial dose of 500 mg/m² is administered intravenously at 3-weekly intervals, accompanied by the oral administration of capecitabine at a therapeutically effective dose such as 1250 mg/m² twice/day for 14 days, followed by 7 days without treatment. The canfosfamide hydrochloride dose may be increased to 750 mg/m² and further to 960 mg/m², and the capecitabine dose may also be varied.

[0073] Canfosfamide hydrochloride at an initial dose of 400 mg/m² is administered intravenously at 2-weekly intervals, followed 30 minutes later by the intravenous administration of fluorouracil at a therapeutically effective dose such as 12 mg/Kg, with leucovorin rescue after completion of four days of fluorouracil therapy. The canfosfamide hydrochloride dose may be increased to 700 mg/m² and further to 1000 mg/m², and the fluorouracil dose may also be varied.

[0074] Ovarian cancer patients treated with carboplatin-containing regimens underwent repeated cycles of alopecia corresponding to the administration of the carboplatin. The same patients, when treated with carboplatin at AUC 5 or 6 mg/mL*min in combination with canfosfamide hydrochloride at 500 mg/m² and carboplatin at AUC 6 mg/mL*min in combination with canfosfamide hydrochloride at 750, and 960 mg/m² did not experience the same recurrence of alopecia with treatment, illustrating the amelioration of this side effect of carboplatin therapy by treatment with canfosfamide hydrochloride. Other side effects such as the hematologic and neurologic side effects of carboplatin were similarly ameliorated.
[0075] Other GST-activated anticancer compounds may be used similarly in the methods of this invention. Different other anticancer therapies, such as other chemotherapies, molecularly targeted therapies, biologic therapies, and radiation therapies may also be used similarly in the methods of this invention and will benefit from the sensitization and/or side effect amelioration induced by treatment with the GST-activated anticancer compounds.

[0076] While this invention has been described in conjunction with specific embodiments and examples, it will be apparent to a person of ordinary skill in the art, having regard to that skill and this disclosure, that equivalents of the specifically disclosed materials and methods will also be applicable to this invention; and such equivalents are intended to be included within the following claims.
We claim:

1. The use of a GST-activated anticancer compound in the manufacture of a medicament for sensitizing a mammal to another anticancer therapy.

2. The use of a GST-activated anticancer compound in the manufacture of a medicament for ameliorating a side effect of another anticancer therapy in a mammal.

3. The use of claim 1 or 2 where the mammal is a human.

4. The use of claim 3 where the GST-activated anticancer compound is a compound of the formula

\[
\begin{align*}
\text{Y} & \quad \text{H} \\
\text{N} & \quad \text{O} \\
\text{AA}_c & \quad \text{S}^x \quad \text{R}^1 \\
\text{R}^2 & \quad \text{R}^3 \\
\text{R}^3 & \quad \text{L}
\end{align*}
\]

or an amide, ester, amide-ester, or salt thereof, where:

- \( L \) is a cytotoxic electron withdrawing leaving group;
- \( S^x \) is \(-\text{S}(\equiv\text{O})_2, \text{-S}(\equiv\text{O})\text{-NH}, \text{-S}(\equiv\text{O})(\text{NH})_2, \text{-S}^x(\text{C}_1\text{-C}_6 \text{ alkyl}), \text{-Se}(\equiv\text{O}), \text{-Se}(\equiv\text{O})_2, \)
- \(-\text{Se}(\equiv\text{NH}), \text{-Se}(\equiv\text{O})(\equiv\text{NH}), \text{or is -O-C}(\equiv\text{O}), \text{or -HN-C}(\equiv\text{O}); \)
- each of \( R^1, R^2 \) and \( R^3 \) is independently \( \text{H} \) or a non-interfering substituent;
- \( n \) is 0, 1 or 2;
- \( Y \) is selected from the group consisting of

\[
\begin{align*}
\text{H}_2\text{NCH(CH}_2\text{)}_m\text{COOH} & \quad \text{HOOC(CH}_2\text{)}_m\text{CHCHCONHCH}_2\text{COOH} \\
\text{NH}_2 & \quad \text{COOH} \\
\text{H}_2\text{NCH(CH}_2\text{)}_m\text{CONHCH}_2\text{COOH} & \quad \text{HOOC(CH}_2\text{)}_m\text{CHCONHCH}_2\text{COOH} \\
\text{NH}_2
\end{align*}
\]

where \( m \) is 1 or 2; and

- \( \text{AA}_c \) is an amino acid linked through a peptide bond to the remainder of the compound.

5. The use of claim 4 where:

- each of \( R^1, R^2 \) and \( R^3 \) is independently \( \text{H}, \) optionally substituted \( \text{C}_1\text{-C}_6 \) alkyl, optionally substituted \( \text{C}_6\text{-C}_{12} \) aryl, optionally substituted \( \text{C}_7\text{-C}_{12} \) aralkyl, cyano, halo, optionally substituted...
C1-C6 alkoxy, optionally substituted C6-C12 aryloxy, or optionally substituted C7-C12 aralkoxy, where the substituents may be halo, -OR, -SR; or -NR3, where R is H or C1-C4 alkyl.

6. The use of claim 4 where:
L is a toxin, a linkable anticancer agent, or a phosphoramidate or phosphorodiamidate mustard; and/or
S is -S(=O)x2; and/or
R1 is H, C1-C4 alkyl, or phenyl; and/or
each R2 is independently chosen from H and C1-C6 alkyl; and/or
each R3 is independently chosen from H, C1-C4 alkyl, and phenyl; and/or
n is 0; and/or
Y-C(=O)- is γ-glutamyl; and/or
AAx is glycine, phenylglycine, β-alanine, alanine, phenylalanine, valine, 4-aminobutyric acid, aspartic acid, histidine, tryptophan, and tyrosine, as either the (S)- or (R)-isomers, optionally substituted on the phenyl ring as described above for R1 through R3.

7. The use of claim 6 where:
L is a phosphorodiamidate mustard of the formula -OP(=O)(NH(CH2CH2X)2 or
-OP(=O)(N(CH2CH2X)2, where X is Cl or Br;
each R1, R2, and R3 is H;
Y-C(=O)- is γ-glutamyl; and
AAx is glycine, phenylglycine, β-alanine, alanine, or phenylalanine.

8. The use of claim 7 where:
L is -OP(=O)(N(CH2CH2Cl)2; and
AAx is (R)-phenylglycine.

9. The use of claim 8 where the GST-activated anticancer compound is canfosfamide or a salt thereof.

10. The use of claim 9 where the GST-activated anticancer compound is canfosfamide hydrochloride.

11. The use of any one of claims 1 to 10 where the another anticancer therapy is selected from one or more of chemotherapy, molecular targeted therapy, biologic therapy, and radiotherapy.
12. The use of claim 11 where the another anticancer therapy is administration of one or more of an alkylating agent, an antimetabolite, a natural product, a hormone or hormone antagonist, a miscellaneous agent, a functional therapeutic agent, a gene therapy agent, an antisense therapy agent, a tyrosine kinase inhibitor, a gene expression modulator, a phenotype-directed therapy agent, a monoclonal antibody, an immunotoxin, a radioimmunoconjugate, a cancer vaccine, an interferon, and an interleukin.

13. The use of claim 12 where the another anticancer therapy is administration of one or more of busulfan, thiotepa, chlorambucil, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, melphalan, uracil mustard, lomustine, streptozocin, dacarbazine, procarbazine, temozolamide, cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, methotrexate, permutrexed, raltitrexed, trimetrexate, cladribine, chlorodeoxyadenosine, clofarabine, fludarabine, mercaptopurine, pentostatin, thioguanine, azacitidine, capecitabine, cytarabine, edatrexate, floxuridine, fluorouracil, gemcitabine, troxacitabine, bleomycin, daclomycin, mithramycin, mitomycin, mitoxantrone, porfiromycin, daunorubicin, daunorubicin, doxorubicin, liposomal doxorubicin, epirubicin, idarubicin, valrubicin, L-asparaginase, PEG-L-asparaginase, paclitaxel, docetaxel, vinblastine, vincristine, vindesine, vinorelbine, irinotecan, topotecan, amsacrine, etoposide, teniposide, fluoxymesterone, testolactone, bicalutamide, cyproterone, flutamide, nilutamide, aminoglutethimide, anastrozole, exemestane, formestane, letrozole, dexamethasone, prednisone, diethylstilbestrol, fulvestrant, raloxifene, tamoxifen, toremifene, buserelin, goserelin, leuprolide, triptorelin, medroxyprogesterone acetate, megestrol acetate, levophthyoxine, lohydroine, altretamine, arsenic trioxide, gallium nitrate, hydroxyurea, levasimole, mitotane, octreotide, procarbazine, suramin, thalidomide, lenalidomide, methoxsalen, sodium porfimer, bortezomib, erlotinib hydrochloride, gefitinib, imatinib mesylate, semaxanib, adapalene, bexarotene, trans-retinoic acid, 9-cis-retinoic acid, N-(4-hydroxyphenyl)retinamide, alemtuzumab, bevacizumab, cetuximab, ibritumomab tiuxetan, rituximab, trastuzumab, gemtuzumab ozogamicin, 131I-tositumomab, interferon-α2a, interferon-α2b, aldesleukin, denileukin diftitox, and oprelvekin.

14. The use of claim 12 where the another anticancer therapy is administration of: a platinum compound, optionally in further combination with gemcitabine or a taxane; gemcitabine; a taxane; an anthracycline; oxaliplatin, optionally in further combination with capecitabine or fluorouracil/leucovorin; and gemcitabine or a platinum compound, in further combination with a vinca alkaloid.
15. The use of claim 14 where the another anticancer therapy is administration of cisplatin or carboplatin.

16. The use of claim 15 where the another anticancer therapy is administration of cisplatin or carboplatin as sole therapy.

17. The use of claim 12 where the another anticancer therapy is administration of two or more of chemotherapy, molecular targeted therapy, biologic therapy, or radiotherapy.

18. The use of claim 12 where the another anticancer therapy is administration of two or more chemotherapy agents.

19. The use of claim 11 where the another anticancer therapy includes radiation therapy.

20. The use of claim 19 where the another anticancer therapy is radiation therapy.

21. The use of any one of claims 1 to 20 where the dosing of the GST-activated anticancer compound is about 5 – 50%, especially about 10 – 50%, of the usual therapeutic dose of that GST-activated anticancer compound, at 1 - 35 day intervals.

22. The use of claim 21 where the dosing is at 1 - 5 week intervals, especially at 1, 2, 3, or 4 week intervals.

23. The use of claim 21 where the GST-activated anticancer compound is canfosfamide hydrochloride and the dosing is about 125 - 450 mg/m² at 1 - 5 week intervals, especially at 1, 2, 3, or 4 week intervals.

24. A pharmaceutical composition for sensitizing a mammal to another anticancer therapy, comprising a GST-activated anticancer compound.


26. The composition of claim 24 or 25 where the mammal is a human.

27. The composition of claim 26 where the GST-activated anticancer compound is a compound of the formula
or an amide, ester, amide-ester, or salt thereof, where:

L is a cytotoxic electron withdrawing leaving group;

$S^\angle$ is $-S(=O)\gamma$, $-S(=O)\gamma\gamma$, $-S(=NH)\gamma$, $-S(=O)(=NH)\gamma$, $-S^\angle(C_1-C_6 \text{ alkyl})\gamma$, $-Se(=O)\gamma$, $-Se(=O)\gamma\gamma$,

$-Se(=NH)\gamma$, or $-Se(=O)(=NH)\gamma$, or is $-O-C(=O)\gamma$, or $-HN-C(=O)\gamma$;

each of $R^1$, $R^2$ and $R^3$ is independently $H$ or a non-interfering substituent;

$n$ is 0, 1 or 2;

Y is selected from the group consisting of

$H_2N(CH_2)_mCONHCH_2$ $COOH$ $HOOC(CH_2)_mCHCONHCH_2$ $COOH$ and $HOOC(CH_2)_mCHCONHCH_2$ $NH_2$

where $m$ is 1 or 2; and

$AA_c$ is an amino acid linked through a peptide bond to the remainder of the compound.

28. The composition of claim 27 where:

each of $R^1$, $R^2$ and $R^3$ is independently $H$, optionally substituted $C_1-C_6 \text{ alkyl}$, optionally

substituted $C_6-C_{12} \text{ aryl}$, optionally substituted $C_7-C_{12} \text{ aralkyl}$, cyano, halo, optionally substituted

$C_1-C_6 \text{ alkoxy}$, optionally substituted $C_6-C_{12} \text{ aryloxy}$, or optionally substituted $C_7-C_{12} \text{ aralkoxy}$,

where the substituents may be halo, -OR, -SR, or -NR$_2$, where R is H or $C_1-C_4 \text{ alkyl}$.

29. The composition of claim 27 where:

L is a toxin, a linkable anticancer agent, or a phosphoramidate or phosphorodiamidate

mustard; and/or

20 $S^\angle$ is $-S(=O)\gamma\gamma$; and/or

$R^1$ is $H$, $C_1-C_4 \text{ alkyl}$, or phenyl; and/or

each $R^2$ is independently chosen from $H$ and $C_1-C_6 \text{ alkyl}$; and/or

each $R^3$ is independently chosen from $H$, $C_1-C_4 \text{ alkyl}$, and phenyl; and/or

$n$ is 0; and/or

25 $Y-C(=O)$ is $\gamma$-glutamyl; and/or
AAₜ is glycine, phenylglycine, β-alanine, alanine, phenylalanine, valine, 4-aminobutyric acid, aspartic acid, histidine, tryptophan, and tyrosine, as either the (S)- or (R)-isomers, optionally substituted on the phenyl ring as described above for R¹ through R³.

30. The composition of claim 29 where:

L is a phosphorodiamidate mustard of the formula -OP(=O)(NHCH₂CH₂X₂)₂ or
-OP(=O)(N(CH₂CH₂X₂)₂, where X is Cl or Br;
each R¹, R², and R³ is H;
Y-C(=O)- is γ-glutamyl; and
AAₜ is glycine, phenylglycine, β-alanine, alanine, or phenylalanine.

31. The composition of claim 30 where:
L is -OP(=O)(N(CH₂CH₂Cl)₂)₂; and
AAₜ is (R)-phenylglycine.

32. The composition of claim 31 where the GST-activated anticancer compound is canfosfamide or a salt thereof.

33. The composition of claim 32 where the GST-activated anticancer compound is canfosfamide hydrochloride.

34. A method of sensitizing a mammal to another anticancer therapy comprising administering a sensitizing effective amount of a GST-activated anticancer compound.

35. A method of ameliorating a side effect of another anticancer therapy in a mammal comprising administering an ameliorating effective amount of a GST-activated anticancer compound.

36. The method of claim 34 or 35 where the mammal is a human.

37. The method of claim 36 where the GST-activated anticancer compound is a compound of the formula
or an amide, ester, or salt thereof, where:
L is a cytotoxic electron withdrawing leaving group;
S^ is \(-S(=O)_2\), \(-S(=O)(=NH)\), \(-S(=O)=N\)H\), \(-S^{(\text{C}_1-\text{C}_6 \text{ alkyl})}\), \(-\text{Se}(=O)_2\), \(-\text{Se}(=O)(=\text{NH})\), or \(-\text{Se}(=\text{NH})_2\); 
5 each of \(R^1\), \(R^2\) and \(R^3\) is independently \(H\) or a non-interfering substituent;
n is 0, 1 or 2;
Y is selected from the group consisting of

\[
\begin{align*}
\text{HOOC(CH}_2\text{)}_m\text{CHCONHCH}_2\text{NH}_2, \\
\text{HOOC(CH}_2\text{)}_m\text{CHCONHCH}_3\text{NH}_2, \\
\text{H}_2\text{NCH(CH}_2\text{)}_m\text{COOH,} \\
\text{H}_2\text{NCH(CH}_2\text{)}_m\text{CONHCH}_2\text{COOH, and}
\end{align*}
\]

where \(m\) is 1 or 2; and
10 \(\text{AA}_c\) is an amino acid linked through a peptide bond to the remainder of the compound.

38. The method of claim 37 where:
each of \(R^1\), \(R^2\) and \(R^3\) is independently \(H\), optionally substituted \(\text{C}_1-\text{C}_6 \text{ alkyl}, \text{optionally substituted C}_6-\text{C}_{12} \text{ aryl, optionally substituted C}_1-\text{C}_{12} \text{ aralkyl, cyano, halo, optionally substituted C}_1-\text{C}_6 \text{ alkoxy, optionally substituted C}_6-\text{C}_{12} \text{ arloxy, or optionally substituted C}_1-\text{C}_{12} \text{ aralkoxy,}
15 where the substituents may be halo, \(-\text{OR}, -\text{SR}, \text{or} -\text{NR}_2)\), where \(R\) is \(H\) or \(\text{C}_1-\text{C}_4 \text{ alkyl}.

39. The method of claim 37 where:
L is a toxin, a linkable anticancer agent, or a phosphoramidate or phosphorodiamidate
mustard; and/or
\(S^\) is \(-S(=O)_2\); and/or
20 \(R^1\) is \(H\), \(\text{C}_1-\text{C}_4 \text{ alkyl, or phenyl; and/or}
each \(R^2\) is independently chosen from \(H\) and \(\text{C}_1-\text{C}_6 \text{ alkyl; and/or}
each \(R^3\) is independently chosen from \(H\), \(\text{C}_1-\text{C}_4 \text{ alkyl, and phenyl; and/or}
n is 0; and/or
Y-\(\text{C}(=\text{O})\)- is \(\gamma\)-glutamyl; and/or
25 \(\text{AA}_c\) is glycine, phenylglycine, \(\beta\)-alanine, alanine, phenylalanine, valine, 4-aminobutyric acid,
aspartic acid, histidine, tryptophan, and tyrosine, as either the \((S)\)- or \((R)\)-isomers, optionally
substituted on the phenyl ring as described above for \(R^1\) through \(R^3\).
40. The method of claim 39 where:

L is a phosphorodiamidate mustard of the formula \(-\text{OP}(=\text{O})(\text{NHCH}_2\text{CH}_2\text{X})_2\) or \\
\(-\text{OP}(=\text{O})(\text{N(CH}_2\text{CH}_2\text{X})_2\)\(_2\))\(_3\), where X is Cl or Br;

each \(R^1\), \(R^2\), and \(R^3\) is H;

5 Y-\(\text{C}(=\text{O})\)- is \(\gamma\)-glutamyl; and

\(\text{AA}_3\) is glycine, phenylglycine, \(\beta\)-alanine, alanine, or phenylalanine.

41. The method of claim 40 where:

L is \(-\text{OP}(=\text{O})(\text{N(CH}_2\text{CH}_2\text{Cl})_2\)\(_2\))\(_3\); and

\(\text{AA}_3\) is (R)-phenylglycine.

42. The method of claim 41 where the GST-activated anticancer compound is canfosfamide or a salt thereof.

43. The method of claim 42 where the GST-activated anticancer compound is canfosfamide hydrochloride.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K38/04 A61K31/282 A61K31/337 A61K31/475 A61K31/00
A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, BIOSIS, WPI Data, PAJ, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>

Additional documents are listed in the continuation box C.

Further documents are listed in the continuation of box C.

X Patent family members are listed in annex.

**A** document defining the general state of the art which is not considered to be of particular relevance

**E** earlier document but published on or after the international filing date

**L** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another document, but is not considered relevant to the particular invention

**O** document referring to an oral disclosure, use, exhibition or other means

**P** document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search: 4 October 2005

Date of mailing of the international search report: 13/10/2005

Name and mailing address of the ISA
European Patent Office, P.O. Box 1076, NL-5600 IA HEERENVEEN
Tél. (+31-70) 340-2060, Fax: (+31-70) 340-3016

Authorized officer
Mateo Rosell, A.M.
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category</td>
<td>Citation of document, with indication, where appropriate, of the relevant passages</td>
<td>Relevant to claim No.</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>P,X</td>
<td>ROSEN L S ET AL: &quot;Phase 1 study of TLK286 (telcyta) administered weekly in advanced malignancies&quot; CLINICAL CANCER RESEARCH 01 JUN 2004 UNITED STATES, vol. 10, no. 11, 1 June 2004 (2004-06-01), pages 3689-3698, XP002345163 ISSN: 1078-0432 the whole document</td>
<td>1-43</td>
</tr>
<tr>
<td>T</td>
<td>KAVANAGH J J ET AL: &quot;Multi-institutional phase 2 study of TLK286 (TELCYTA(TM), a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer&quot; INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 2005 UNITED STATES, vol. 15, no. 4, 2005, pages 593-600, XP002345164 ISSN: 1048-891X the whole document</td>
<td></td>
</tr>
<tr>
<td>Category *</td>
<td>Citation of document, with indication, where appropriate, of the relevant passages</td>
<td>Relevant to claim No.</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td></td>
<td>&amp; EXPERT REVIEW OF ANTICANCER THERAPY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2005 UNITED KINGDOM,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>vol. 5, no. 1, 2005, pages 139-147,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ISSN: 1473–7140</td>
<td></td>
</tr>
</tbody>
</table>
# INTERNATIONAL SEARCH REPORT

**Box II** Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **X** Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
   
   Although claims 34-43 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. □ Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. □ Claims Nos.: because they are dependent claims and are not crafted in accordance with the second and third sentences of Rule 6.4(a).

**Box III** Observations where unity of Invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. □ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. □ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. □ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. □ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AU 676618 B2</td>
<td>13-03-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 7962394 A</td>
<td>01-05-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2173130 A1</td>
<td>13-04-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69424298 D1</td>
<td>08-06-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69424298 T2</td>
<td>31-08-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 721465 T3</td>
<td>14-08-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2147244 T3</td>
<td>01-09-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 3033226 T3</td>
<td>31-08-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 9506074 T</td>
<td>17-06-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 721465 T</td>
<td>31-10-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9509866 A1</td>
<td>13-04-1995</td>
</tr>
</tbody>
</table>

|                                      |                 | CA 2505377 A1           | 03-06-2004      |
|                                      |                 | EP 1562564 A2           | 17-08-2005      |